Safety and Efficacy Study of the Amaranth Medical APTITUDE Bioresorbable Drug-Eluting Coronary Stent

PHASE2UnknownINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

April 30, 2017

Study Completion Date

July 31, 2021

Conditions
Coronary Artery DiseaseMyocardial Ischemia
Interventions
DEVICE

AmM APTITUDE Bioresorbable Drug-Eluting Coronary Scaffold

Placement of the investigational device into the diseased coronary artery to eliminate the vascular stenosis.

Trial Locations (12)

Unknown

Clinica de Marly, Bogotá

Instituto del Corazon, Bucaramanga

EMMSA Clinica Especializada, Medellín

Angiografia De Occidente S.A., Santiago de Cali

Azienda Policlinico-Vittorio Emanuele, Universita di Catania, Catania

Azienda Ospedaliero Universitaria Careggi, Florence

Azienda Ospedaliera Fatebenefratelli e Oftalmico, Milan

Ospedale San Raffaele, Milan

Policlinico San Donato, Milan

A. O. U. Federico II˚ Policlinico, Napoli

Policlinico Universitario, Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua

A. O. Ordine Mauriziano Umberto I, Torino

Sponsors
All Listed Sponsors
lead

Amaranth Medical Inc.

INDUSTRY